Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Opko, Alnylam, Santaris, and More

Premium

Title: Natural Antisense and Non-Coding RNA Transcripts as Drug Targets

Patent Number: 8,288,354

Filed: Dec. 28, 2006

Inventor: Claes Wahlestedt, Scripps Research Institute (Opko Health)

“Small interfering RNA knock down antisense transcripts, and regulate the expression of their sense partners,” the patent's abstract states. “This regulation can either be discordant — antisense knockdown results in sense transcript elevation — or concordant — antisense knockdown results in concomitant sense transcript reduction.”


Title: siRNA Specific to WT1 17AA(-) Isoform and Use Thereof

Patent Number: 8,288,355

Filed: March 28, 2007

Lead Inventor: Haruo Sugiyama, International Institute of Cancer Immunology

The invention, the patent's abstract states, comprises an siRNA that acts as a “cancer cell-specific molecular-targeted therapy, which successfully controls the function of WT1.”


Title: microRNAs

Patent Number: 8,288,356

Filed: Oct. 3, 2008

Lead Inventor: Susanna Obad, Santaris Pharma

The invention relates to “very short, heavily modified oligonucleotides [that] target and inhibit microRNAs in vivo and their use in medicaments and pharmaceutical compositions,” according to the patent's abstract.


Title: Use of Inhibitors of Leukotriene B4 Receptor BLT2 for Treating Human Cancers

Patent Number: 8,288,357

Filed: March 24, 2008

Lead Inventor: Jae-Hong Kim, Korea University Research & Business Foundation

The invention relates to a “pharmaceutical composition for treating human cancers comprising BLT2 inhibitors and a method for treating human cancers using BLT2 inhibitors,” the patent's abstract states. “BLT2 has an important role in metastasis of cancer cells and angiogenesis of tumor and ... the anti-cancer activity of the BLT2 inhibitors is accomplished by inducing the apoptosis of cancer cells, inhibiting the metastasis of cancer cells, or inhibiting the angiogenesis of tumor.”

The patent specifically claims BLT2-targeted siRNAs.


Title: Therapeutic Targets and Molecules

Patent Number: 8,288,358

Filed: March 26, 2008

Lead Inventor: Paul Stephen Foster, Newcastle Innovation

“The invention provides methods and compositions for treating or preventing inflammation or an inflammatory condition in a subject, comprising administering to the subject an effective amount of at least one antagonist of one or more [microRNA] up-regulated in inflammatory disease conditions and response to allergen challenge,” the patent's abstract states. “The invention also provides methods for diagnosing inflammatory conditions based on miRNA expression profile signatures.”


Title: Compositions and Methods for Inhibiting Expression of CD45 Gene

Patent Number: 8,288,525

Filed: Oct. 27, 2010

Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the CD45 gene,” according to the patent's abstract.


Title: Method of Delivering RNA Interference and Uses Thereof

Application Number: 20120258534

Filed: March 29, 2012

Lead Inventor: Judy Lieberman, Immune Disease Institute (Harvard University)

The invention, the patent application's abstract states, comprises “contacting the cell with a fusion protein-double-stranded RNA complex, the complex comprising ... a double-stranded RNA of interest and a fusion protein.” The fusion protein comprises a “targeting moiety, which will specifically bind to a site on a target cell, and a binding moiety, which will bind to the double-stranded RNA.”


Title: Methods and Compositions for the Specific Inhibition of Gene Expression by Double-Stranded RNA

Application Number: 20120258535

Filed: June 8, 2012

Lead Inventor: John Rossi, City of Hope (Integrated DNA Technologies)

“The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene,” the patent application's abstract states. “More particularly, the invention is directed to compositions that contain double-stranded RNA, and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.”


Title: siRNA Targeting Proto-Oncogene MET

Application Number: 20120258888

Filed: June 12, 2012

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for MET.”


Title: siRNA Targeting Kinase Insert Domain Receptor

Application Number: 20120258889

Filed: June 15, 2012

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR.”


Title: Duplex Oligonucleotides with Enhanced Functionality in Gene Regulation

Application Number: 20120259001

Filed: April 30, 2012

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

The invention, the patent application's abstract states, comprises “methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics [that] contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions.”

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.